Skip to main content

Table 2 Subgroup analysis based on cancer type

From: Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer

OutcomeSubgroupNumber of trialsEffect (95%CI)Overall effect estimateHeterogeneity
1-Year OSGC11.54 (0.99, 2.39)P = 0.056
CRC21.42 (1.21, 1.66)P < 0.001I2 = 54.1%, P = 0.140
3-Year OSGC31.29 (1.12, 1.48)P < 0.001I2 = 0%, P = 0.937
CRC22.03 (1.41, 2.93)P < 0.001I2 = 0%, P = 0.782
5-Year OSGC21.79 (1.31, 2.45)P < 0.001I2 = 26.8%, P = 0.242
CRC21.94 (1.18, 3.20)P = 0.009I2 = 0%, P = 0.634
1-Year PFSGC11.41 (0.88, 2.26)P = 0.155
CRC21.33 (1.11, 1.60)P = 0.002I2 = 0%, P = 0.940
3-Year PFSGC31.36 (1.14, 1.61)P = 0.001I2 = 0%, P = 0.377
CRC21.49 (1.10, 2.01)P = 0.010I2 = 0%, P = 0.980
5-Year PFSGC22.25 (1.54, 3.29)P < 0.001I2 = 0%, P = 0.493
CRC21.73 (1.19, 2.52)P = 0.004I2 = 0%, P = 0.854
PRGC21.58 (0.70, 3.59)P = 0.275I2 = 0%, P = 0.685
CRC12.52 (0.71, 8.97)P = 0.154
ORRGC21.30 (0.81, 2.09)P = 0.278I2 = 0%, P = 0.457
CRC12.36 (0.79, 7.05)P = 0.124
QOLGC128 (26.36, 29.64)P < 0.001
CRC29.32 (6.96, 11.69)P < 0.001I2 = 0%, P = 0.373
  1. CRC Colorectal cancer, GC gastric cancer, ORR overall response rate, OS overall survival, PFS progression-free survival, PR partial response, QOL quality of life